drugset / Trial / NCT03402295
Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study compared two main different induction protocols used to treat myeloma eligible patients in Brazil. VCD against CTD.
Timeline
- Start
- 2009-06-15
- Primary completion
- 2014-06-15
- Completion
- 2017-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Comparator | Cyclophosphamide | Other / unclassified | 900 mg | Intravenous |
| Comparator | Cyclophosphamide | Other / unclassified | 2000 mg | Intravenous |
| Comparator | Dexamethasone | Small molecule | 40 mg | Oral |
| Comparator | Thalidomide | Other / unclassified | 100 mg | Oral |
| Comparator | Thalidomide | Other / unclassified | 200 mg | Oral |